TRPS1 is a promising marker for all subtypes of breast cancer

Abstract

AimsTrichorhinophalangeal syndrome‐1 (TRPS1) has been proposed as a novel breast marker with equally high expression in breast cancer (BC) subtypes, making it a useful diagnostic tool. Here, its expression was evaluated alongside other commonly used markers [GATA3, GCDFP15, mammaglobin (MGB) and SOX10] in a large cohort of BCs (n = 1852) and their corresponding nodal metastases. Its usefulness as a diagnostic tool and its correlation with clinicopathological features were assessed.Methods and resultsTRPS1 was expressed at 75.8% overall in the BC cohort, with at least 58% expression among BC subtypes. It was less sensitive than GATA3 for luminal and HER2‐overexpressing (HER2‐OE) cancers (luminal A: 82 versus 97%; luminal B: 80 versus 95%; HER2‐OE: 62 versus 76%), but it was the most sensitive for TNBC (60 versus ≤ 41%). It showed a stable expression in nodal metastases (primary tumour 76 versus nodal metastasis 78%), unlike a reduced nodal expression for GATA3 (86 versus 77%). TRPS1 outperformed GATA3 in detecting non‐luminal cancers when paired with other breast markers. TRPS1 and GCDFP15 was the most sensitive combination in TNBC detection, with a 76% detection rate. For TRPS1‐negative and GCDFP15‐negative TNBCs, SOX10 was more sensitive than GATA3 (29 versus 24%).ConclusionsTRPS1 is a highly sensitive marker for all breast cancer subtypes, outperforming GATA3 in non‐luminal cancers and displaying the highest sensitivity for TNBC detection when combined with GCDFP15. It is a valuable addition to the breast marker panel for accurate identification of BC.